Annual Net Income
-$1.78 M
-$434.00 K-32.20%
31 December 2023
Summary:
XTL Biopharmaceuticals annual net profit is currently -$1.78 million, with the most recent change of -$434.00 thousand (-32.20%) on 31 December 2023. During the last 3 years, it has risen by +$1.17 million (+39.68%). XTLB annual net income is now -149.09% below its all-time high of $3.63 million, reached on 31 December 2018.XTLB Net Income Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly Net Income
$485.00 K
+$769.00 K+270.77%
31 March 2024
Summary:
XTL Biopharmaceuticals quarterly net profit is currently $485.00 thousand, with the most recent change of +$769.00 thousand (+270.77%) on 31 March 2024. Over the past year, it has increased by +$700.00 thousand (+325.58%). XTLB quarterly net income is now -87.48% below its all-time high of $3.87 million, reached on 01 March 2019.XTLB Quarterly Net Income Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM Net Income
-$378.00 K
+$1.40 M+78.79%
31 March 2024
Summary:
XTL Biopharmaceuticals TTM net profit is currently -$378.00 thousand, with the most recent change of +$1.40 million (+78.79%) on 31 March 2024. Over the past year, it has increased by +$1.87 million (+83.17%). XTLB TTM net income is now -105.70% below its all-time high of $6.63 million, reached on 01 March 2019.XTLB TTM Net Income Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
XTLB Net Income Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | -32.2% | +325.6% | +83.2% |
| 3 y3 years | +39.7% | +161.0% | +86.2% |
| 5 y5 years | -149.1% | +138.6% | -126.0% |
XTLB Net Income High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | -509.7% | +39.7% | -76.8% | +152.8% | -124.8% | +86.8% |
| 5 y | 5 years | -149.1% | +39.7% | -76.8% | +138.6% | -124.8% | +91.5% |
| alltime | all time | -149.1% | +92.8% | -87.5% | +105.8% | -105.7% | +98.5% |
XTL Biopharmaceuticals Net Income History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Mar 2024 | - | $485.00 K(-270.8%) | -$378.00 K(-78.8%) |
| Dec 2023 | -$1.78 M(+32.2%) | -$284.00 K(+32.1%) | -$1.78 M(-20.7%) |
| Sept 2023 | - | -$215.00 K(-40.9%) | -$2.25 M(-21.2%) |
| June 2023 | - | -$364.00 K(-60.4%) | -$2.85 M(+2.8%) |
| Mar 2023 | - | -$919.00 K(+22.9%) | -$2.77 M(+105.7%) |
| Dec 2022 | -$1.35 M(-409.9%) | -$748.00 K(-8.9%) | -$1.35 M(-190.2%) |
| Sept 2022 | - | -$821.00 K(+188.1%) | $1.50 M(-1.7%) |
| June 2022 | - | -$285.00 K(-156.3%) | $1.52 M(+131.9%) |
| Mar 2022 | - | $506.00 K(-75.8%) | $656.00 K(+50.5%) |
| Dec 2021 | $435.00 K(-114.7%) | $2.10 M(-363.5%) | $436.00 K(-115.9%) |
| Sept 2021 | - | -$795.00 K(-30.9%) | -$2.73 M(+0.8%) |
| June 2021 | - | -$1.15 M(-502.1%) | -$2.71 M(+8.7%) |
| Mar 2021 | - | $286.00 K(-126.6%) | -$2.50 M(-4.3%) |
| Dec 2020 | -$2.95 M(+287.2%) | -$1.08 M(+39.2%) | -$2.61 M(+26.7%) |
| Sept 2020 | - | -$773.00 K(-17.1%) | -$2.06 M(-19.0%) |
| June 2020 | - | -$932.00 K(-638.7%) | -$2.54 M(-43.1%) |
| Mar 2020 | - | $173.00 K(-132.9%) | -$4.46 M(+485.1%) |
| Dec 2019 | -$763.00 K(-121.0%) | -$526.00 K(-58.2%) | -$763.00 K(-152.5%) |
| Sept 2019 | - | -$1.26 M(-56.0%) | $1.45 M(-61.1%) |
| June 2019 | - | -$2.85 M(-173.7%) | $3.74 M(-43.6%) |
| Mar 2019 | - | $3.87 M(+129.1%) | $6.63 M(+82.6%) |
| Dec 2018 | $3.63 M(-564.8%) | $1.69 M(+64.2%) | $3.63 M(+87.4%) |
| Sept 2018 | - | $1.03 M(+2929.4%) | $1.94 M(-22.3%) |
| June 2018 | - | $34.00 K(-96.1%) | $2.49 M(+132.8%) |
| Mar 2018 | - | $875.00 K(<-9900.0%) | $1.07 M(-237.1%) |
| Dec 2017 | -$781.00 K(-69.3%) | -$2000.00(-100.1%) | -$781.00 K(-60.6%) |
| Sept 2017 | - | $1.59 M(-214.3%) | -$1.98 M(-48.5%) |
| June 2017 | - | -$1.39 M(+42.1%) | -$3.86 M(+30.9%) |
| Mar 2017 | - | -$977.00 K(-18.9%) | -$2.94 M(+15.7%) |
| Dec 2016 | -$2.54 M(-41.0%) | -$1.21 M(+321.3%) | -$2.54 M(-31.3%) |
| Sept 2016 | - | -$286.00 K(-40.0%) | -$3.71 M(-4.1%) |
| June 2016 | - | -$477.00 K(-17.3%) | -$3.86 M(+1.3%) |
| Mar 2016 | - | -$577.00 K(-75.6%) | -$3.81 M(-11.6%) |
| Dec 2015 | -$4.31 M(+50.5%) | -$2.37 M(+433.9%) | -$4.31 M(+41.3%) |
| Sept 2015 | - | -$443.00 K(+3.7%) | -$3.05 M(-2.1%) |
| June 2015 | - | -$427.00 K(-60.3%) | -$3.12 M(-4.2%) |
| Mar 2015 | - | -$1.08 M(-2.7%) | -$3.25 M(+13.6%) |
| Dec 2014 | -$2.87 M(-22.8%) | -$1.11 M(+116.9%) | -$2.87 M(-30.9%) |
| Sept 2014 | - | -$510.00 K(-9.4%) | -$4.15 M(+34.3%) |
| June 2014 | - | -$563.00 K(-17.9%) | -$3.09 M(-12.5%) |
| Mar 2014 | - | -$686.00 K(-71.3%) | -$3.53 M(-5.0%) |
| Dec 2013 | -$3.71 M | -$2.39 M(-534.8%) | -$3.71 M(+128.9%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2013 | - | $549.00 K(-154.7%) | -$1.62 M(-27.0%) |
| June 2013 | - | -$1.00 M(+15.0%) | -$2.22 M(+17.3%) |
| Mar 2013 | - | -$872.00 K(+194.6%) | -$1.89 M(+36.2%) |
| Dec 2012 | -$1.39 M(+15.2%) | -$296.00 K(+492.0%) | -$1.39 M(+0.6%) |
| Sept 2012 | - | -$50.00 K(-92.6%) | -$1.38 M(-17.2%) |
| June 2012 | - | -$675.00 K(+82.9%) | -$1.67 M(+31.0%) |
| Mar 2012 | - | -$369.00 K(+28.1%) | -$1.27 M(+5.6%) |
| Dec 2011 | -$1.21 M(-4.0%) | -$288.00 K(-14.5%) | -$1.21 M(-2.2%) |
| Sept 2011 | - | -$337.00 K(+20.4%) | -$1.23 M(+4.0%) |
| June 2011 | - | -$280.00 K(-7.3%) | -$1.19 M(-2.9%) |
| Mar 2011 | - | -$302.00 K(-4.1%) | -$1.22 M(-2.7%) |
| Dec 2010 | -$1.26 M(-148.6%) | -$315.00 K(+8.6%) | -$1.26 M(+2.2%) |
| Sept 2010 | - | -$290.00 K(-8.2%) | -$1.23 M(+32.1%) |
| June 2010 | - | -$316.00 K(-6.0%) | -$931.00 K(-255.7%) |
| Mar 2010 | - | -$336.00 K(+16.7%) | $598.00 K(-76.9%) |
| Dec 2009 | $2.59 M(-114.0%) | -$288.00 K(-3300.0%) | $2.59 M(-147.0%) |
| Sept 2009 | - | $9000.00(-99.3%) | -$5.50 M(-18.6%) |
| June 2009 | - | $1.21 M(-26.6%) | -$6.76 M(-41.4%) |
| Mar 2009 | - | $1.65 M(-119.7%) | -$11.54 M(-31.1%) |
| Dec 2008 | -$18.43 M(-26.1%) | -$8.38 M(+569.9%) | -$16.75 M(+100.2%) |
| Sept 2008 | - | -$1.25 M(-64.8%) | -$8.37 M(-37.3%) |
| June 2008 | - | -$3.56 M(-0.0%) | -$13.35 M(-22.0%) |
| Mar 2008 | - | -$3.56 M(<-9900.0%) | -$17.12 M(-18.0%) |
| Dec 2007 | -$24.94 M(+64.8%) | $0.00(-100.0%) | -$20.88 M(-15.8%) |
| Sept 2007 | - | -$6.23 M(-14.9%) | -$24.80 M(+10.3%) |
| June 2007 | - | -$7.33 M(0.0%) | -$22.49 M(+19.6%) |
| Mar 2007 | - | -$7.33 M(+86.9%) | -$18.81 M(+24.3%) |
| Dec 2006 | -$15.13 M(+8.0%) | -$3.92 M(-0.0%) | -$15.13 M(-3.9%) |
| Sept 2006 | - | -$3.92 M(+7.5%) | -$15.74 M(-3.7%) |
| June 2006 | - | -$3.65 M(0.0%) | -$16.35 M(+7.7%) |
| Mar 2006 | - | -$3.65 M(-19.5%) | -$15.18 M(+8.3%) |
| Dec 2005 | -$14.02 M(-14.9%) | -$4.53 M(-0.0%) | -$14.02 M(+3.0%) |
| Sept 2005 | - | -$4.53 M(+82.9%) | -$13.60 M(+3.1%) |
| June 2005 | - | -$2.48 M(0.0%) | -$13.19 M(-16.2%) |
| Mar 2005 | - | -$2.48 M(-39.9%) | -$15.75 M(-9.4%) |
| Dec 2004 | -$16.47 M(+15.3%) | -$4.12 M(+0.0%) | -$17.39 M(+31.0%) |
| Sept 2004 | - | -$4.12 M(-18.2%) | -$13.27 M(+45.0%) |
| June 2004 | - | -$5.03 M(+22.2%) | -$9.15 M(+122.2%) |
| Mar 2004 | - | -$4.12 M | -$4.12 M |
| Dec 2003 | -$14.29 M(-16.6%) | - | - |
| Dec 2002 | -$17.14 M(+35.2%) | - | - |
| Dec 2001 | -$12.67 M | - | - |
FAQ
- What is XTL Biopharmaceuticals annual net profit?
- What is the all time high annual net income for XTL Biopharmaceuticals?
- What is XTL Biopharmaceuticals annual net income year-on-year change?
- What is XTL Biopharmaceuticals quarterly net profit?
- What is the all time high quarterly net income for XTL Biopharmaceuticals?
- What is XTL Biopharmaceuticals quarterly net income year-on-year change?
- What is XTL Biopharmaceuticals TTM net profit?
- What is the all time high TTM net income for XTL Biopharmaceuticals?
- What is XTL Biopharmaceuticals TTM net income year-on-year change?
What is XTL Biopharmaceuticals annual net profit?
The current annual net income of XTLB is -$1.78 M
What is the all time high annual net income for XTL Biopharmaceuticals?
XTL Biopharmaceuticals all-time high annual net profit is $3.63 M
What is XTL Biopharmaceuticals annual net income year-on-year change?
Over the past year, XTLB annual net profit has changed by -$434.00 K (-32.20%)
What is XTL Biopharmaceuticals quarterly net profit?
The current quarterly net income of XTLB is $485.00 K
What is the all time high quarterly net income for XTL Biopharmaceuticals?
XTL Biopharmaceuticals all-time high quarterly net profit is $3.87 M
What is XTL Biopharmaceuticals quarterly net income year-on-year change?
Over the past year, XTLB quarterly net profit has changed by +$700.00 K (+325.58%)
What is XTL Biopharmaceuticals TTM net profit?
The current TTM net income of XTLB is -$378.00 K
What is the all time high TTM net income for XTL Biopharmaceuticals?
XTL Biopharmaceuticals all-time high TTM net profit is $6.63 M
What is XTL Biopharmaceuticals TTM net income year-on-year change?
Over the past year, XTLB TTM net profit has changed by +$1.87 M (+83.17%)